German health reform hits Beiersdorf's sales:
This article was originally published in Clinica
Beiersdorf's domestic medical sales continue to be hit by the effects of German health reform and subsequent uncertainty following "complicated" regulatory change. Total sales in this division fell 1.6% to DM756 million ($427 million) in the first half of 1998, as a result of reduced sales in Germany. The Hamburg-based company's group sales were DM3,420 million, up 6%, with net income of DM159 million, compared with DM146 million - excluding restructuring costs - in the previous first half.